Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • ASCO Journal Club • Non-Hodgkin Lymphoma • Hematology • Mantle Cell Lymphoma
What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?
Answer from: Medical Oncologist at Academic Institution
Not all post-protocol therapy was reported; however, nearly 20% of patients who were treated with pirtobrutinib on trial went on to receive CAR-T therapy. Pirtobrutinib’s ideal use is dependent on patient and disease characteristics. In the BRUIN trial, the median PFS, DOR, and OS of MCL patie...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
There is limited data on the outcomes of patients following pirtobrutinib but clinically, we have used this drug as a bridge to CAR-T in younger healthier patients, and for older frailer patients, we have used this drug until progression. With a rapidly evolving landscape in MCL, the role of these a...